However, the increase in plasma CX3CL1 levels is not congruent with tissue levels, which are decreased in the hippocampus and frontal cortex of advanced AD cases [43], suggesting variable roles of CX3CL1 in different stages of AD pathogenesis. This evidence concerns the gene CX3CL1 and Alzheimer disease.